From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials

Thomas Lam, John W. Hetherington, John Greenman, Anthony Maraveyas

Research output: Contribution to journalLiterature review

24 Citations (Scopus)

Abstract

'Metronomic chemotherapy' represents a novel anti-angiogenic strategy whereby low-dose chemotherapy is utilized in a continuous fashion in order to target tumor endothelium. There are many potential advantages of this strategy and clinical trials are already underway. However, although the scheduling of metronomic chemotherapy is relatively unequivocal, metronomic dosing principles are at present poorly defined. Arbitrarily, 10-33% of the maximum tolerated dose comprises 'the dose range'. We argue that this is too empirical and propose a set of phase I metronomic chemotherapy dosing strategies based on a principled approach which may help to reduce the problem of empiricism in dosing for metronomic chemotherapy trials.
Original languageEnglish
Pages (from-to)113-121
Number of pages9
JournalAnti-Cancer Drugs
Volume17
Issue number2
DOIs
Publication statusPublished - Feb 2006

Keywords

  • endothelial growth cells
  • growth factor
  • metastatic colorectal cancer
  • low dose cycophosphamide
  • acquired drug resistance
  • tumor angiogenesis
  • breast cancer
  • cell proliferation
  • stem cells
  • survival
  • therapy

Fingerprint Dive into the research topics of 'From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials'. Together they form a unique fingerprint.

  • Cite this